Mark Chouinard, MD
Cardiovascular Disease · Blair, NENPI 1487615316
Payments from drug & device makers
Across 679 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$3K
- Novartis$3K
- E.r. Squibb & Sons, L.L.C.$1K
- Johnson & Johnson$1K
- Pfizer$804
- Esperion Therapeutics, Inc.$510
- plus $4K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 105 | $2,555 |
| Novartis | 185 | $2,527 |
| E.r. Squibb & Sons, L.L.C. | 58 | $1,276 |
| Johnson & Johnson | 73 | $1,210 |
| Pfizer | 54 | $804 |
| Esperion Therapeutics, Inc. | 26 | $510 |
| Boehringer Ingelheim | 28 | $501 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 18 | $433 |
| Merck | 19 | $402 |
| Sanofi-aventis U.S. LLC | 22 | $385 |
| Actelion Pharmaceuticals US, Inc. | 14 | $330 |
| Bridgebio Pharma, Inc. | 5 | $202 |
| Bayer | 6 | $197 |
| Amarin Pharma, Inc. | 9 | $139 |
| Boston Scientific | 6 | $123 |
| Alnylam Pharmaceuticals Inc. | 1 | $120 |
| Kiniksa Pharmaceuticals, Ltd. | 6 | $100 |
| Scpharmaceuticals Inc. | 4 | $87 |
| Regeneron Healthcare Solutions, Inc. | 5 | $84 |
| Abiomed | 3 | $83 |
| AstraZeneca | 5 | $77 |
| Lexicon Pharmaceuticals, Inc. | 3 | $64 |
| Heartflow, Inc. | 2 | $52 |
| Gilead | 4 | $51 |
| Daiichi Sankyo Inc. | 3 | $44 |
| Kiniksa Pharmaceuticals International, PLC | 3 | $43 |
| Azurity Pharmaceuticals, Inc. | 2 | $32 |
| Lundbeck LLC | 2 | $24 |
| Altathera Pharmaceuticals LLC | 1 | $20 |
| Zimmer Biomet | 1 | $20 |
| Baxter Healthcare | 1 | $19 |
| Sanofi | 1 | $18 |
| Impulse Dynamics (USA) Inc. | 1 | $17 |
| Abbott | 1 | $15 |
| Chiesi USA, Inc. | 1 | $14 |
| United Therapeutics Corporation | 1 | $13 |
How this compares
$12,588 in reported general payments places this provider in the 75th percentile of 97 cardiovascular disease providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other cardiovascular disease in Blair
- Ronald ZoltyOmaha$6.3M
- Robert PercellLincoln$1.3M
- Steven KruegerLincoln$840K
- Chad TraversLincoln$594K
- Jeffrey CarstensOmaha$299K
- Joseph ThibodeauOmaha$251K
- Keith MillerLincoln$204K
- John SteuterLincoln$190K
- Edward OlearyOmaha$104K
- Michael PetersOmaha$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.